

WT1 126-134 Circular RNA for Cancer Vaccine Research

Catalog Number:CVAC-ORNA-0489

| DESCRIPTION | |
|-------------------|---|
| Product Name | WT1 126-134 Circular RNA for Cancer Vaccine Research |
| Gene Name | WT1 126-134 |
| Source | In vitro transcribed mRNA was further circularized to make this product as a circular RNA. |
| Alternative names | WT1 126-134 Peptide Vaccine |
| SPECIFICATIONS | |
| Cap | |
| 5'-UTR | 5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence |
| ORF | WT1 126-134 |
| 3'-UTR | 3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA |
| Poly(A) Tail | |
| Modifications | N1-methyl-pseudouridine |
| Neutral Lipid | 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) |
| Cholesterol | Cholesterol |
| Ionizable Lipid | 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG) |
| PEG-lipid | Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102) |
| Storage | -80 °C |
| Buffer | PBS, pH7.5 |
| Cryoprotectant | Trehalose |
| BACKGROUND | |
| Gene Accession | |
| Gene Alias | WT1 126-134 Peptide Vaccine |
| Background | Description: A synthetic peptide vaccine consisting of the amino acids 126 through 134 of the human Wilms' Tumor protein-1 (WT1) with potential antitumor activity. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. Vaccination with WT1 126-134 peptide vaccine may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. (NCIT_C61442). |



Seattle Genova

Tel: +1 (425) 247-3088 Fax: +1 (425) 650-9990

Email: info@seattle-genova.com Web: www.seattle-genova.com

Address: 18110 SE 34TH ST STE 455, Vancouver, WA 98683
